These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 33548250)

  • 1. Double expressor and double/triple hit status among primary cutaneous diffuse large B-cell lymphoma: a comparison between leg type and not otherwise specified subtypes.
    Lucioni M; Pescia C; Bonometti A; Fraticelli S; Moltrasio C; Ramponi A; Riboni R; Roccio S; Ferrario G; Arcaini L; Goteri G; Berti E; Paulli M
    Hum Pathol; 2021 May; 111():1-9. PubMed ID: 33548250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High Incidence and Clinical Significance of MYC Rearrangements in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
    Schrader AMR; Jansen PM; Vermeer MH; Kleiverda JK; Vermaat JSP; Willemze R
    Am J Surg Pathol; 2018 Nov; 42(11):1488-1494. PubMed ID: 30113335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma.
    Huang S; Nong L; Wang W; Liang L; Zheng Y; Liu J; Li D; Li X; Zhang B; Li T
    Diagn Pathol; 2019 Jul; 14(1):81. PubMed ID: 31315646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological, cytogenetic, and molecular profiles of primary cutaneous diffuse large B-cell lymphomas.
    Uccella S; Goteri G; Maiorana A; Donati V; Tibiletti MG; Magnoli F; Facchi S; Merchiori D; Morsia E; Papotti R; Bettelli S; Forti E; Galimberti S; Rupoli S; Filosa A; Dardanis D; Bomben R; Braglia L; Pozzi S; Sacchi S
    Hum Pathol; 2023 Jun; 136():44-55. PubMed ID: 36997030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MYC single-hit large B-cell lymphoma: clinicopathologic difference from MYC-negative large B-cell lymphoma and MYC double-hit/triple-hit lymphoma.
    Cho YA; Hyeon J; Lee H; Cho J; Kim SJ; Kim WS; Ko YH
    Hum Pathol; 2021 Jul; 113():9-19. PubMed ID: 33771538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: Biopsy analysis of 70 cases from the Slovak Lymphoma Registry.
    Lešková K; Szépe P; Balhárek T; Barthová M; Janáková Ľ; Farkašová A; Plank L
    Neoplasma; 2022 Jul; 69(4):957-964. PubMed ID: 35652622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary cutaneous B-cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers.
    Lucioni M; Berti E; Arcaini L; Croci GA; Maffi A; Klersy C; Goteri G; Tomasini C; Quaglino P; Riboni R; Arra M; Dallera E; Grandi V; Alaibac M; Ramponi A; Rattotti S; Cabras MG; Franceschetti S; Fraternali-Orcioni G; Zerbinati N; Onida F; Ascani S; Fierro MT; Rupoli S; Gambacorta M; Zinzani PL; Pimpinelli N; Santucci M; Paulli M
    Cancer Med; 2016 Oct; 5(10):2740-2755. PubMed ID: 27665744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of primary central nervous system large B-cell lymphoma in the era of high-grade B-cell lymphoma: Detection of two cases with MYC and BCL6 rearrangements in a cohort of 12 cases.
    Pina-Oviedo S; Bellamy WT; Gokden M
    Ann Diagn Pathol; 2020 Oct; 48():151610. PubMed ID: 32889391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-hit or dual expression of MYC and BCL2 in primary cutaneous large B-cell lymphomas.
    Menguy S; Frison E; Prochazkova-Carlotti M; Dalle S; Dereure O; Boulinguez S; Dalac S; Machet L; Ram-Wolff C; Verneuil L; Gros A; Vergier B; Beylot-Barry M; Merlio JP; Pham-Ledard A
    Mod Pathol; 2018 Aug; 31(8):1332-1342. PubMed ID: 29581544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased CD11c-positive dendritic cells in the tumor microenvironment predict double-hit/triple-hit genotype and survival in diffuse large B-cell lymphoma.
    Yuan CT; Chuang SS; Cheng PY; Chang K; Wang H; Tsai JH; Liau JY; Chou WC
    J Pathol Clin Res; 2022 Sep; 8(5):436-447. PubMed ID: 35715938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas.
    Pillai RK; Sathanoori M; Van Oss SB; Swerdlow SH
    Am J Surg Pathol; 2013 Mar; 37(3):323-32. PubMed ID: 23348205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
    Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
    J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colorectal diffuse large B-cell lymphoma: molecular subclassification and prognostic significance of immunoglobulin gene translocation.
    Hori Y; Yamamoto H; Nozaki Y; Torisu T; Fujiwara M; Taguchi K; Nishiyama K; Nakamura S; Kitazono T; Oda Y
    Hum Pathol; 2020 Feb; 96():67-78. PubMed ID: 31734190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients with double/triple copy number gains on C-MYC, BCL2, and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomas.
    Willenbacher E; Willenbacher W; Weger R; Dominik W; Manzl C; Brunner A
    Ann Hematol; 2020 Sep; 99(9):2125-2132. PubMed ID: 32613279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified.
    Yan LX; Liu YH; Luo DL; Zhang F; Cheng Y; Luo XL; Xu J; Cheng J; Zhuang HG
    PLoS One; 2014; 9(8):e104068. PubMed ID: 25090026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Significance of
    Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
    Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
    [No Abstract]   [Full Text] [Related]  

  • 17. MYC, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type.
    Nosrati A; Monabati A; Sadeghipour A; Radmanesh F; Safaei A; Movahedinia S
    Ann Hematol; 2019 Jan; 98(1):169-173. PubMed ID: 30306208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic aberrations in primary cutaneous large B-cell lymphoma: a fluorescence in situ hybridization study of 25 cases.
    Wiesner T; Streubel B; Huber D; Kerl H; Chott A; Cerroni L
    Am J Surg Pathol; 2005 May; 29(5):666-73. PubMed ID: 15832092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomas.
    Huang W; Medeiros LJ; Lin P; Wang W; Tang G; Khoury J; Konoplev S; Yin CC; Xu J; Oki Y; Li S
    Mod Pathol; 2018 Sep; 31(9):1470-1478. PubMed ID: 29785017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.
    Ye Q; Xu-Monette ZY; Tzankov A; Deng L; Wang X; Manyam GC; Visco C; Montes-Moreno S; Zhang L; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Møller MB; Piris MA; Winter JN; Medeiros LJ; Hu S; Young KH
    Oncotarget; 2016 Jan; 7(3):2401-16. PubMed ID: 26573234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.